In the era of personalized medicine and targeted therapies for the management of patients
with cancer, ultrasensitive detection methods for tumor genotyping, such as next-generation …

Tyrosine kinase inhibitors (TKIs) have vastly improved long-term outcomes for patients with
chronic myeloid leukemia (CML). After imatinib (a first-generation TKI), second-and third …

Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for
measuring gene expression, doing clonality assays and detecting hot spot mutations. In …

The digital polymerase chain reaction (dPCR) is considered to be the third-generation
polymerase chain reaction (PCR), as it yields direct, absolute and precise measures of …

New techniques are on the horizon for the detection of small leukemic clones in both, acute
leukemias and myeloproliferative disorders. A promising approach is based on digital …

Leukemia is a deadly cancer disease, and according to World Health Organization (WHO)
data, there were 437,033 cases across the world in 2018. Early detection of this cancer is …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by the BCR-ABL1
fusion gene generation as a consequence of the t (9; 22)(q34; q11) rearrangement. The …

Molecular monitoring of minimal residual disease (MRD) and BCR-ABL1 kinase domain
(KD) mutation testing have a well consolidated role in the routine management of chronic …

Accurate detection of BCR-ABL fusion transcripts at and below molecular response (MR) 4
(0.01% International Scale [IS]) is required for disease monitoring in patients with chronic …

The primary goal of tyrosine kinase inhibitor (TKI) therapy for patients with chronic myeloid
leukemia is survival, which is achieved by the vast majority of patients. The initial response …